Why Malaria Matters: Voices of Glion

07 May 2002

At an MMV stakeholders' meeting in 2002, stakeholders and Board Members speak about why malaria matters and promise an exciting new model for malaria R&D. Today, MMV has lived up to its promises. See our achievements and learn about current R&D challenges.

"If you were interested and wanted to associate yourself with a proven, viable business model and enterprise with highly committed people, with experts, with an established funding base, then there is probably no better choice than MMV".

- Steven Phillips, Exxon Mobil Corporation

"We are demonstrating that it is possible, using public funds through this product public partnership to fund high quality, basic research that will lead eventually into a pharmaceutical product. It is a new way of doing things".

- Dr. William Charman, Monash University, Australia